Oscar Health – 2025-11-25 - increase Confidence 7/10

OSCR – increase in Days/Weeks

Oscar Health generated $515.9 million in levered free cash flow and holds $3.04 billion in cash, signaling strong liquidity despite a trailing net loss of $244.09 million. The stock surged 25.15% on November 24, 2025, on news of a potential two-year ACA subsidy extension, which would boost enrollment and premium stability.

Why This Matters

The combination of improving operational efficiency—evidenced by stronger cost controls and a refined membership mix—and a favorable policy catalyst in the ACA subsidy extension creates a near-term tailwind for Oscar Health. With the company leaning heavily on its tech-enabled +Oscar platform to scale profitably, even without current profitability, the market is pricing in reduced regulatory and demand risk, making the stock sensitive to legislative sentiment in the short window before year-end.

Key Insights

• Free Cash Flow & Cash Position: $515.9M levered FCF and $3.04B cash provide runway and strategic flexibility
• News Impact: Proposed ACA subsidy extension directly supports Oscar’s core individual marketplace business, lifting sentiment and volume
• Risk/Offset: High beta (1.878) and negative net income expose OSCR to sentiment swings; analyst consensus remains “Moderate Sell” with 15% downside to $13.82 target

Practical Implications

• Bull Case: ACA extension confirmed or advanced in legislation → momentum continuation toward $20+ in 2–3 weeks
• Bear Case: Subsidy talks stall or analysts downgrade → profit-taking could push price back to $14–$15 range
• Confidence: 7/10 – Strong news-driven momentum and solid cash flow offset weak earnings; short-term catalyst dominates fundamentals

Prediction: increase

Reference:

• https://tokenist.com/oscar-health-stock-jumps-after-report-of-obamacare-subsidy-extension-proposal/
• https://www.fool.com/coverage/filings/2025/11/24/oscar-health-s-transition-continues-following-a-stake-reduction-by-glynn-capital/